Search Results

BioVentrix, Inc., a privately held medical device company developing minimally invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process in patients with congestive heart failure, announced the completion of $48.5 million Series A round financing.

BioVentrix ® , Inc today announced the appointment of Ori Ben-Yehuda, MD as Chief Medical Officer (CMO).

BioVentrix®, Inc. today announced the publication of a peer-reviewed paper in the Journal of Clinical Medicine, titled, Inward Displacement, A Novel Approach to Measuring Left Ventricular (LV) Function in Patients with HFrEF after Undergoing BioVentrix Therapy.

BioVentrix ® , Inc. today announced the US Food and Drug Administration (FDA) has approved its application for an Expanded Access Program (EAP) for Revivent TC® System.

BioVentrix, Inc. today announced that it has acquired MateraCor, Inc.

BioVentrix, Inc ., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter-based Ventricular Restoration (TCVR), today announced that Jim Dillon has been named President and CEO.

BioVentrix, Inc. today announced the appointment of Raymond W. Cohen as the Company’s chairman and named Rinda K. Sama and Andrew G. Hinson to its board of directors.

BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter based Ventricular Restoration (TCVR), today announced that the German Institute for Hospital Remuneration (InEK) has renewed the NUB Status 1 reimbursement designation in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System used in LIVE™ Therapy (Less Invasive Ventricular Enhancement).

BioVentrix, Inc. , a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE Trial studying LIVE™ Therapy using the Revivent TC™ TransCatheter Ventricular Enhancement System . He join

BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that it has been named by FierceMedTech as one of the “Fierce 15” for 2019, designating it as one of the most promising private medtech companies in the industry.